Questions about patients' participation in the following clinical trials can be directed to Jane Rabbitt or Margaretta Page by calling 415.353.2966, or by email to Valerie Kivett at kivettv@neurosurg.ucsf.edu.

**Newly Diagnosed Malignant Glioma**

A Phase I/II Study of Enzastaurin plus Temozolomide During and Following Radiation Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme and Gliosarcoma

A Phase II/III Randomized Study of CDX-110 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme

**Newly Diagnosed Low-Grade Glioma**

A Phase I Study of Temozolomide (SCH 52365) in the Treatment of Adult Patients with Supratentorial Low-Grade Glioma

**Recurrent Tumor**

Phase II, 2-Part, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 (Angiocept™) Monotherapy and Combination Therapy with Irinotecan in Patients with Recurrent Glioblastoma Multiforme

A Phase I Study of Vorinostat (SAHA) and Temozolomide in Patients with Malignant Glioma (NABTC 04-03)

**Non-Chemotherapy Protocols**

San Francisco Bay Area Adult Glioma Prognosis Study. A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas

**Adult Clinical Trials in Development**

A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients with Recurrent High-Grade Gliomas

A Phase 2 Study of XL184 in Subjects with Progressive or Recurrent Glioblastoma Multiforme in First or Second Relapse

Phase I/II trial of Oncophage (Heat Shock Protein Peptide Complex-96) Vaccine For Patients With Recurrent High Grade Glioma

Phase II Studies of BAY 43-9006 (sorafenib) in Combination with OSI-774 (erlotinib), R115777 (tipifarnib) or CCI-779 (temsirolimus) in Patients with Recurrent Glioblastoma Multiforme or Gliosarcoma (NABTC05-02)

A Phase II study of Bevacizumab plus Temodar and Tarceva after Radiation Therapy and Temodar in Patients with Newly Diagnosed Glioblastoma or Gliosarcoma who are Stable Following Radiation

Phase II Study Of 7 Days On/7 Days Off Temozolomide In Patients With High-Grade Glioma

Phase II Study of Tarceva in Patients with Recurrent EGFR Positive and PTEN Wild Type Glioblastoma Multiforme and Gliosarcoma

To enroll patients in neuro-oncology adult clinical trials call (415) 353-2996
Questions about patients’ participation in the following clinical trials can be directed to Cynthia Asiyo by calling 415.476.3982 or by e-mail at AsiyoC@peds.ucsf.edu. Alternatively, to contact the nurse practitioner in charge, please call 415.476.3831.

For further details about clinical trials for children being performed through the Pediatric Brain Tumor Center (PBTC), visit: http://www.pbtc.org.

For further details about clinical trials for children being performed through the Children's Oncology Group, visit: http://clinicaltrials.gov.

Newly Diagnosed Tumor

Diffuse Pontine Glioma

Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas (PBTC 021)

A Phase II Study of Motetaxin-Gadolinium (NSC #695238, IND #55583) and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood (Children's Oncology Group Study ACNS0222)

High-grade Glioma

Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas (PBTC 021)

Low-grade Glioma

A Phase II Study of Conformal Radiotherapy in Patients with Low-Grade Gliomas; a Groupwide Phase II Study (Children's Oncology Group Study ACNS0221)

Medulloblastoma and Primitive Neural Ectodermal Tumor

A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial (Children’s Oncology Group Study ACNS0331)

Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients (Children's Oncology Group Study ACNS0332)

A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy Without Methotrexate (Children’s Oncology Group Study ACNS0334)

Germ Cell Tumor

Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors (Children’s Oncology Group Study ACNS0122)

Radiotherapy Alone vs. Chemotherapy Followed By Response-based Radiotherapy For Newly Diagnosed Primary CNS Germinoma (Children’s Oncology Group Study ACNS0232)

Recurrent Disease

Phase I/II Study of Lapatinib (GW572016) in Pediatric Patients with Recurrent or Refractory Medulloblastoma, Malignant Glioma, or Ependymoma (PBTC 016)

Phase I Trial of CC-5013 (Lenalidomidae) in Pediatric Patients with Recurrent or Refractory Primary CNS Tumors (PBTC 018)

A Phase I Pharmacokinetic Optimal Dosing Study of Intrathecal Topotecan for Children with Neoplastic Meningitis (PBTC 019)

Phase I Clinical Trial of AZD2171 in Children with Recurrent or Progressive Central Nervous System (CNS) Tumors (PBTC 020)

Phase II study of Bevacizumab plus Irinotecan (Camptosar™) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas and Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, and Ependymomas (PBTC 022)

Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents with Refractory Primary CNS Tumors (PBTC 023)

A Phase I/II Safety and Exploratory Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects with Relapsed/Refractory Solid Tumors (Wyeth Protocol #3066K1-139-US)

A Phase II Study of Pemetrexed in Children with Recurrent Malignancies (Children’s Oncology Group Study ADVL0525)

Pediatric Clinical Trials in Development

A Phase I Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children with Solid Tumors (Amgen Study 20050252)

A Phase I Study Of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children with Refractory Solid Tumors (Children's Oncology Group Study ADVL0612)

To enroll patients in neuro-oncology pediatric clinical trials call (415) 476-3982